Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Southwest General Partners with Notable to Close Care Gaps and Redefine Patient Access

    IBM aims for quantum computer in 2029, lays out road map for larger systems

    Ong Beng Seng to plead guilty on Jul 3, in case involving former minister Iswaran

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest VKontakte
    Sg Latest NewsSg Latest News
    • Home
    • Politics
    • Business
    • Technology
    • Entertainment
    • Health
    • Sports
    Sg Latest NewsSg Latest News
    Home»Health»HUM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
    Health

    HUM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

    AdminBy AdminNo Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    NEWTOWN, Pa., June 9, 2025 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Humana Inc. (“Humana”) (NASDAQ: HUM), resulting from allegations of providing potentially misleading business information to the investing public.

    If you have non-public information that could assist in the Humana investigation, or if you are a Humana investor who suffered a loss and would like to learn more, you can provide your information HERE.

    You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 or via e-mail at [email protected].

    THE COMPANY:

    Humana Inc. is a for-profit health insurance company offering Medicare Advantage, individual and group insurance, pharmacy benefit management, and integrated care services through its CenterWell network.

    THE ALLEGED WRONGDOING:

    On June 5, 2025, The Wall Street Journal reported that Humana, the fourth-largest health insurance company in the U.S., would support congressional efforts to reform Medicare billing practices that generate billions of dollars in extra payments for the health insurance industry. Specifically, the company indicated its support for restrictions on payments for home-visit diagnoses, which accounted for $15 billion in revenue for Medicare Advantage insurers between 2019 and 2021. This report came one month after the Department of Justice filed a False Claims Act Complaint against Humana and other major insurers for allegedly providing insurance brokers with “hundreds of millions” in kickbacks in exchange for enrolling customers in Medicare Advantage plans between 2016 and 2021.

    Following the announcement of the DOJ lawsuit, Humana’s stock declined $6.20 per share, or 2.36%, to close at $256.04 per share on May 1, 2025.

    ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to securities and investment fraud cases, our lawyers focus on class cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft, data security, and consumer fraud.

    For more information, please contact:

    Marc H. Edelson, Esq.
    Eric Lechtzin, Esq.
    EDELSON LECHTZIN LLP
    411 S. State Street, Suite N-300
    Newtown, PA 18940
    Phone: 844-696-7492 ext. 1
    Email: [email protected]
    Email: [email protected]
    Web:  www.edelson-law.com 

    This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so counsel does not represent you unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing now. Your ability to share in any potential future recovery depends not on serving as lead plaintiff.

    SOURCE Edelson Lechtzin LLP

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Admin
    • Website

    Related Posts

    Southwest General Partners with Notable to Close Care Gaps and Redefine Patient Access

    New hope for children with cancer

    How Long Does Ketamine Pain Relief Last? Real Timeline

    Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

    Add A Comment
    Leave A Reply Cancel Reply

    Editors Picks

    Microsoft’s Singapore office neither confirms nor denies local layoffs following global job cuts announcement

    Google reveals “material 3 expressive” design – Research Snipers

    Trump’s fast-tracked deal for a copper mine heightens existential fight for Apache

    Top Reviews
    9.1

    Review: Mi 10 Mobile with Qualcomm Snapdragon 870 Mobile Platform

    By Admin
    8.9

    Comparison of Mobile Phone Providers: 4G Connectivity & Speed

    By Admin
    8.9

    Which LED Lights for Nail Salon Safe? Comparison of Major Brands

    By Admin
    Sg Latest News
    Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
    • Get In Touch
    © 2025 SglatestNews. All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.